CNSP
CNS Pharmaceuticals, Inc. NASDAQ$7.84
Mkt Cap $4.5M
52w Low $1.90
18.1% of range
52w High $34.80
50d MA $2.59
200d MA $5.91
P/E (TTM)
-0.1x
EV/EBITDA
0.3x
P/B
0.2x
Debt/Equity
0.1x
ROE
-350.5%
P/FCF
-0.2x
RSI (14)
—
ATR (14)
—
Beta
0.49
50d MA
$2.59
200d MA
$5.91
Avg Volume
32.7K
About
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceutica…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -5.37 | -10.15 | -89.0% | 2.39 | +12.1% | -4.6% | -5.4% | -2.9% | -8.8% | -8.8% | — |
| Nov 14, 2025 | AMC | -6.63 | -5.76 | +13.1% | 6.90 | -3.0% | -2.9% | -2.5% | -2.5% | -5.7% | +0.0% | — |
| Aug 14, 2025 | AMC | -9.60 | -6.42 | +33.1% | 6.03 | +4.6% | -15.6% | +2.7% | -10.3% | +15.6% | +0.7% | — |
| Nov 14, 2024 | AMC | -0.10 | -150.06 | -9999.0% | 71.40 | -0.3% | -11.6% | +0.8% | +6.6% | +3.9% | +9.2% | — |
| Aug 14, 2024 | AMC | -3585.43 | -4033.61 | -12.5% | 83.16 | -5.5% | +1.7% | -4.3% | +4.2% | +22.8% | +19.8% | — |
| May 15, 2024 | AMC | — | -12304.92 | — | 5988.00 | -3.8% | +12.7% | +8.7% | +8.2% | +7.7% | +3.7% | — |
| Apr 1, 2024 | AMC | -57000.00 | -28511.40 | +50.0% | 10794.00 | +0.1% | -14.5% | -18.7% | -21.8% | -28.1% | -37.7% | — |
| Nov 14, 2023 | AMC | -51900.00 | -32412.97 | +37.5% | 50100.00 | +4.2% | +15.0% | +25.7% | +59.9% | +47.3% | +25.1% | — |
| Aug 14, 2023 | AMC | -84600.00 | -31212.48 | +63.1% | 53100.00 | -1.1% | -3.4% | +2.8% | +6.2% | +2.3% | -31.1% | — |
| May 15, 2023 | AMC | — | -77731.09 | — | 41700.00 | -2.9% | -10.8% | -7.9% | -2.9% | +14.4% | +27.3% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 12 | Maxim Group | Upgrade | Hold → Buy | — | $7.52 | $7.82 | +4.0% | -1.7% | +22.3% | +21.5% | +16.1% | +16.2% |
| Mar 25 | Maxim Group | Downgrade | Buy → Hold | — | $40.56 | $18.12 | -55.3% | -51.8% | -58.3% | -60.9% | -61.5% | -59.8% |
| Feb 2 | Brookline Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 24 | Ladenburg Thalmann | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Dec 4 | Benchmark | Maintains | Speculative Buy → Buy | — | — | — | — | — | — | — | — | — |
Recent Filings
8-K · 5.02
!!! Very High
CNS Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
CNS Pharmaceuticals appointed Michal Fisher as director while Gumulka resigned, signaling potential strategic shifts in the company's board governance and leadership direction.
May 4
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
CNSP's investor presentation signals management confidence in upcoming developments, likely indicating positive clinical or operational updates that could drive near-term stock appreciation if execution meets expectations.
Mar 11
8-K · 5.02
!!! Very High
CNS Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
CNS Pharmaceuticals loses director Lynne Kelley, effective March 2, 2026, potentially affecting board oversight and governance as the company navigates its pharmaceutical development pipeline.
Mar 2
8-K · 5.02
!!! Very High
CNS Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
CNS Pharmaceuticals appointed a new executive with a $450,000 base salary, 40% bonus target, and 9,500 restricted stock units, signaling leadership continuity and commitment to retention.
Feb 17
Data updated apr 25, 2026 2:20am
· Source: massive.com